Date: 2016-03-07
Type of information: Nomination
Compound:
Company: Avacta (UK)
Therapeutic area: Diagnostic
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 3, 2016, Avacta announced that the company has established a scientific advisory board. Avacta has appointed three leading immunologists, Professors Terence Rabbitts, Paul Moss and Adrian Hayday, to form its Scientific Advisory Board which is to be chaired by Non-Executive Director Dr Mike Owen.
Dr Owen was Senior Vice President and Global Head of Research of the Biopharmaceuticals R&D Unit at GSK where he was responsible for initiating and rapidly growing GSK's robust pre-clinical and clinical therapeutic antibody pipeline during the last decade through in-house development and through acquisitions such as Domantis. He was appointed as Non-Executive Director of Avacta in September 2015 to bring extensive clinical trial, scientific and commercial experience of therapeutic development and to establish and chair a Scientific Advisory Board to support the development of Affimers as a therapeutic platform technology.
Avacta has now appointed three pre-eminent biologists to form the Scientific Advisory Board: Professor Terrence Rabbitts of the University of Oxford and John Radcliffe Hospital, Professor Adrian Hayday of the Crick Institute King’s College and Guy’s Hospital, and Professor Paul Moss, Director of the School of Cancer Sciences at Birmingham University and Honorary Consultant at the University Hospitals Birmingham NHS Foundation Trust.
Financial terms:
Latest news:
